Withaferin A [5119-48-2]

Catalog number: AG-CN2-0490-M001
Brand: AdipoGen Life Sciences
Packing: 1 mg
Other sizes: 5 mg
10 mg
Price: € 80.00
Expected delivery time: 7 days
Quantity:
Chemical Structure
Chemical Structure...

Product specifications for - Withaferin A [5119-48-2]

Overview: 
Product group: Lysates / Extracts
Category: Other
Source: Isolated from Withania somnifera.
CAS No.: 5119-48-2
Properties: 
Purity: >98%
Molecular Formula: C28H38O6
Molecular weight: 470.6
Datasheet: Datasheet
  Research Use Only
UNSPSC: 41105330
Scientific information: 
Scientific info: Chemical. CAS: 5119-48-2. Formula: C28H38O6. MW: 470.6. Isolated from Withania somnifera. Multifunctional anticancer compound. Amplifies the cellular antioxidant and/or detoxification system, suppresses inflammatory pathways, selectively inhibits tumor cell proliferation and induces apoptosis, suppresses tumor angiogenesis, blocks epithelial-to-mesenchymal transition (EMT), tumor invasion and metastasis, alters tumor cell metabolism, induces immunomodulation and downregulates cancer stem cells targets. Sensitizes resistant cancer cells to existing chemotherapeutic agents. Antioxidant. Induces cytoprotective enzymes (Nrf2-dependent as well), including SOD, HO-1 (heme oxygenase-1), catalase, glutathione peroxidise, glutathione s-transferase and NQO1. Anti-inflammatory agent. Inhibits COX-2 and iNOS expression (at protein and mRNA level) and PGE2 production. Prevents NF-kappaB activation by inhibiting activation of IKKbeta. Inhibits Helicobacter pylori-induced IL-1beta production by regulating NF-kappaB and directly inhibiting NLRP3 inflammasome activation. Antiproliferative agent. Induces G2/M phase cell cycle arrest, targeting CDKs. Shown to modulate STAT3, Bcl2, Notch receptors, Akt, Hsp90, EGFR, HER2 and PCNA. Disrupts the organization of microtubules and actin/microfilament. Stimulates F-actin cross-linking. Induces tumor cell apoptosis. Shown to induce ROS production. Activates mitochondrial apoptosis pathway through Bcl-2 downregulation and Bax upregulation. Shown to induce p53-dependent pathways and ER-stress. Activates the tumor suppressor protein PAR-4. Directly or indirectly inhibits selected other kinases, such MAPK or STAT3. Shown to inhibit hedgehog signalling pathway. Described to be an autophagy inducer and inhibitor. Potent inhibitor of the 20S proteasome beta5 subunit chymotrypsin-like activity. Potent angiogenesis inhibitor by modulating VEGF. Antimigratory, antiinvasive and antimetastatic compound. Targets TGF-beta, vimentin, MMPs and Notch receptors. Inhibits cancer stem cells targets, including aldehyde dehydrogenase 1 (ALDH1) activity. Alters cell line-specific the mRNA expression of cancer stem cell markers, such as Oct4, SOX-2, and Nanog. Reported to induce neuronal regeneration. Antidiabetic compound. Potent Leptin sensitizer, acting similar to Celastrol (Prod. No. AG-CN2-0460). - Multifunctional anticancer compound. Amplifies the cellular antioxidant and/or detoxification system, suppresses inflammatory pathways, selectively inhibits tumor cell proliferation and induces apoptosis, suppresses tumor angiogenesis, blocks epithelial-to-mesenchymal transition (EMT), tumor invasion and metastasis, alters tumor cell metabolism, induces immunomodulation and downregulates cancer stem cells targets. Sensitizes resistant cancer cells to existing chemotherapeutic agents. Antioxidant. Induces cytoprotective enzymes (Nrf2-dependent as well), including SOD, HO-1 (heme oxygenase-1), catalase, glutathione peroxidise, glutathione s-transferase and NQO1. Anti-inflammatory agent. Inhibits COX-2 and iNOS expression (at protein and mRNA level) and PGE2 production. Prevents NF-kappaB activation by inhibiting activation of IKKbeta. Inhibits Helicobacter pylori-induced IL-1beta production by regulating NF-kappaB and directly inhibiting NLRP3 inflammasome activation. Antiproliferative agent. Induces G2/M phase cell cycle arrest, targeting CDKs. Shown to modulate STAT3, Bcl2, Notch receptors, Akt, Hsp90, EGFR, HER2 and PCNA. Disrupts the organization of microtubules and actin/microfilament. Stimulates F-actin cross-linking. Induces tumor cell apoptosis. Shown to induce ROS production. Activates mitochondrial apoptosis pathway through Bcl-2 downregulation and Bax upregulation. Shown to induce p53-dependent pathways and ER-stress. Activates the tumor suppressor protein PAR-4. Directly or indirectly inhibits selected other kinases, such MAPK or STAT3. Shown to inhibit hedgehog signalling pathway. Described to be an autophagy inducer and inhibitor. Potent inhibitor of the 20S proteasome beta5 subunit chymotrypsin-like activity. Potent angiogenesis inhibitor by modulating VEGF. Antimigratory, antiinvasive and antimetastatic compound. Targets TGF-beta, vimentin, MMPs and Notch receptors. Inhibits cancer stem cells targets, including aldehyde dehydrogenase 1 (ALDH1) activity. Alters cell line-specific the mRNA expression of cancer stem cell markers, such as Oct4, SOX-2, and Nanog. Reported to induce neuronal regeneration. Antidiabetic compound. Potent Leptin sensitizer, acting similar to Celastrol (Prod. No. AG-CN2-0460).
Safety information: 
MSDS: MSDS
Antitumor activity of withaferin A (NSC-101088): B. Shohat, et al.; Cancer Chemother. Rep. 51, 271 (1967) Read more
Withaferin A is a potent inhibitor of angiogenesis: R. Mohan, et al.; Angiogenesis 7, 115 (2004) Read more
Neuritic regeneration and synaptic reconstruction induced by withanolide: A: T. Kuboyama, et al.; Br. J. Pharmacol. 144, 961 (2005) Read more
The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry": H. Yang, et al.; Mol. Pharmacol. 71, 426 (2007) Read more
The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin: P. Bargagna-Mohan, etal.; Chem. Biol. 14, 623 (2007) Read more
Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade: C. Mandal, et al.; Apoptosis 13, 1450 (2008) Read more
Inhibition of monosodium urate crystal-induced inflammation by withaferin A: E.P. Sabina, et al.; J. Pharm. Pharm. Sci. 11, 46 (2008) Read more
Withaferin A targets heat shock protein 90 in pancreatic cancer cells: Y. Yu, et al.; Biochem. Pharmacol. 79, 542 (2010) Read more
Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis: S. Koduru, et al.; Mol. Cancer Ther. 9, 202 (2010) Read more
Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells: J. Lee, et al.; Carcinogenesis. 31, 1991 (2010) Read more